Randomized, open-label, controlled, comparative study on switching HIV-infected patients with their antiretroviral therapy experience to a DTG and 3TC regimen: 96-weeks results
- Authors: Kanestri V.G.1,2, Kravchenko A.V.1, Pokrovskaya A.V.1,3, Kulabukhova E.I.1,3, Kuimova U.A.1, Goliusova M.D.1, Kozyrina N.V.1, Shakhgildyan V.I.1,2, Yurin O.G.1
-
Affiliations:
- Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being
- H-Clinic University Clinic
- Peoples' Friendship University of Russia
- Issue: Vol 11, No 4 (2021)
- Pages: 45-52
- Section: Articles
- URL: https://journals.eco-vector.com/2226-6976/article/view/287829
- DOI: https://doi.org/10.18565/epidem.2021.11.4.45-52
- ID: 287829
Cite item
Abstract
Keywords
Full Text
About the authors
Veronika G. Kanestri
Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being; H-Clinic University Clinic
Email: kanestri@yandex.ru
MD, Senior Researcher
Alexey V. Kravchenko
Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being
Email: alexey-kravtchenko@yandex.ru
МБ, Leading Researcher
Anastasia V. Pokrovskaya
Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being; Peoples' Friendship University of Russia
Email: pokrovskaya_av@mail.ru
Cand. Med. Sci., Senior Researcher
Ekaterina I. Kulabukhova
Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being; Peoples' Friendship University of Russia
Email: ekulabukhova@mail.ru
Cand. Med. Sci., Infectiologist
Ulyana A. Kuimova
Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being
Email: ulyanakuimova@gmail.com
Cand. Med. Sci., Researcher
Marina D. Goliusova
Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being
Email: mad2501@yandex.ru
Infectiologist
Nadezhda V. Kozyrina
Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being
Email: nad-kozyrina@yandex.ru
Cand. Med. Sci., Senior Researcher
Vasiliy I. Shakhgildyan
Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being; H-Clinic University Clinic
Email: vishakh@yandex.ru
Cand. Med. Sci., Senior Researcher
Oleg G. Yurin
Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being
Email: oleg_gerald@mail.ru
МD, Leading Researcher
References
- Cahn P., Andrade-'Villanueva J., Arribas J.R., Gatell J.M., Lama J.R., Norton J.R.et al. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. Lancet Infect. Dis. 2014; 14(7): 572-80. doi: 10.1016/S1473-3099(14)70736-4
- Di Giambenedetto S., Fabbiani M., Quiros Roldan E., Latini А., D’Ettorre G., Antinori А. et al. Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). J. Antimicrob Chemother. 2017; 72(4): 1163-71. doi: 10.1093/jac/dkw557
- Raffi F., Babiker A.G., Richert L., Molina J.-M., George Е.С., Antinori А., Arribas J.R. et al. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet 2014; 384(9958): 1942-51. doi: 10.1016/ S0140-6736(14)61170-3
- Perez-Molina J.A., Pulido F., Di Giambenedetto S., Ribera Е., Moreno S, Zamora J., Coscia С. et al. Individual patient data meta-analysis of randomized controlled trials of dual therapy with a boosted PI plus lamivudine for maintenance of virological suppression: GeSIDA study 9717. J. Antimicrob Chemother. 2018; 73(11): 2927-35. doi: 10.1093/ jac/dky299
- Cahn P., Rol6n M.J., Figueroa M.I. et al. Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir Lamivudin E) study. J. Int. AIDS Soc. 2017; 20(1): 21678. doi: 10.7448/ IAS.20.01.21678
- Taiwo B.O., Zheng L., Stefanescu A. et al. ACTG A5353: a pilot study of dolutegravir plus lamivudine for initial treatment of human immunodeficiency virus-1 (HIV-1)-infected participants with HIV-1 RNA № 500 000 copies/ml. Clin. Infect. Dis. 2018; 66(11): 1689-97. doi: 10.1093/cid/ cix1083
- Brenner B.G., Wainberg M.A. Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance. Virus Res. 2017; 239: 1-9. doi: 10.1016/j.virusres.2016.07.006
- Cahn P., Madero J.S., Arribas J.R. et al. Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials. J. Acquir. Immune Defic. Syndr, 2020; 83(3): 310-8. doi: 10.1097/QAI.0000000000002275
- Cahn P., Sierra Madero J.,Arribas J.R., Antinori A., Ortiz R., Clarke A.E. et al. Durable Efficacy of Dolutegravir (DTG) Plus Lamivudine (3TC) In Antiretroviral Treatment-Naive Adults With Hiv-1 Infection 3-Year Results From The GEMINI Studies. HIV Drug Therapy Glasgow; 2020; Virtual; Poster P018.
- Van Wyk J., Ajana F., Bisshop F., De Wit S., Osiyemi O., Sogorb J. P. et al. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study. Clin. Infect. Dis. 2020; 71(8): 1920-9. doi: 10.1093/cid/ ciz1243
- Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Developed by the panel on clinical practices for treatment of HIV infection convened by the Department of Health and Human Services (DHHS). AIDS info, 2021. https://clinicalinfo.hiv.gov/en/guidelines
- EACS Guidelines. Version 10.1. October 2020. http://www.eacsociety.org
- Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel. JAMA 2020; 324(16): 1651-69. doi: 10.1001/jama.2020.17025
- Покровский В.В., Юрин О.Г., Кравченко А.В., Беляева В.В., Буравцова Е.В., Деулина М.О. и др. Рекомендации по лечению ВИЧ-инфекции и связанных с ней заболеваний, химиопрофилактике заражения ВИЧ. Эпидемиол. инфекц. болезни. Актуал. вопр. 2020; 10 (4, приложение), 92 с.